Alankrita Taneja
Overview
Explore the profile of Alankrita Taneja including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
49
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Atrash S, Robinson M, Taneja A, Paul B, Cassetta K, Ndiaye A, et al.
Eur J Haematol
. 2023 Jun;
111(3):373-381.
PMID: 37311695
Background: Ki-67 is an index of proliferative activity and is an established predictive and prognostic marker in multiple malignancies. However, its prognostic relevance in multiple myeloma (MM) is unclear. We...
2.
Mishra R, Dima D, Kumar S, Mian A, Taneja A, Karna R, et al.
Hematol Oncol
. 2023 Jun;
41(5):884-893.
PMID: 37309225
With improvement in survival after chronic lymphocytic leukemia (CLL) diagnosis, the real-world burden of second hematological malignancies (SHM) has not been comprehensively assessed in recent era. We analyzed risk, incidence,...
3.
Taneja A, Jain T
EJHaem
. 2022 Jul;
3(Suppl 1):32-38.
PMID: 35844301
Chimeric antigen receptor (CAR) T-cell is the most recent version in the evolution of cellular therapy with promising responses, which has revolutionized the management of some hematological malignancies in the...
4.
Gupta R, Gupta A, Hillengass J, Holstein S, Suman V, Taneja A, et al.
Expert Rev Anticancer Ther
. 2022 May;
22(5):457-469.
PMID: 35503516
Introduction: Recent advances in the diagnosis and management of multiple myeloma (MM) have improved patient outcomes. This progress in our understanding of MM has resulted in continuous suppressive therapy concepts,...
5.
Krishnamurti L, Ross D, Sinha C, Leong T, Bakshi N, Mittal N, et al.
J Med Internet Res
. 2019 Dec;
21(12):e14462.
PMID: 31799940
Background: Hydroxyurea, chronic blood transfusions, and bone marrow transplantation are efficacious, disease-modifying therapies for sickle cell disease but involve complex risk-benefit trade-offs and decisional dilemma compounded by the lack of...
6.
Taneja A, Kumar V, Chandra A
Eur J Haematol
. 2019 Nov;
104(5):390-399.
PMID: 31769538
Objective: Primary renal lymphoma (PRL) is defined as a non-Hodgkin lymphoma (NHL) restricted to kidneys without extensive nodal disease. The literature on epidemiology and outcome in PRL is limited to...
7.
Taneja A, Jones J, Pittaluga S, Maric I, Farooqui M, Ahn I, et al.
Leuk Lymphoma
. 2018 Jul;
60(2):519-522.
PMID: 29978754
No abstract available.
8.
Saad A, Taneja A, Di Stasi A, Sarmad R, Kukkamalla R, Costa L, et al.
Bone Marrow Transplant
. 2018 May;
53(10):1345-1348.
PMID: 29728698
No abstract available.
9.
Taneja A, Das S, Hussain S, Madadin M, Lobo S, Fatima H, et al.
Sci Eng Ethics
. 2018 Feb;
25(2):635-642.
PMID: 29423621
Being inherently different from any other lifesaving organ transplant, uterine transplantation does not aim at saving lives but supporting the possibility to generate life. Unlike the kidneys or the liver,...
10.
Yadav P, Sathian B, Sherchan R, Fatima H, Sharan K, Hussain S, et al.
Asian Pac J Cancer Prev
. 2017 Dec;
18(12):3213-3215.
PMID: 29281869
Childhood cancers form a rare and heterogeneous group which fortunately have a higher cure rate than adult
cancers. A few non-profit organizations in Nepal have extended support to help patients...